Загрузка...
The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
Radiation therapy is potentially immunogenic yet it rarely generates long-term antitumor effects. We have recently demonstrated that Toll-like receptor 9 (TLR9) jump-starts the signal transduction and activator of transcription 3 (STAT3)-dependent vascularization and regrowth of tumors that recur up...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Landes Bioscience
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4203530/ https://ncbi.nlm.nih.gov/pubmed/25340001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.27894 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|